* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mineralys Therapeutics's EV-to-EBIT
For the Biotechnology subindustry, Mineralys Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's EV-to-EBIT falls into.
Mineralys Therapeutics's current Enterprise Value is $674.10 Mil.
Mineralys Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Mineralys Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $117.18 Mil.
Mineralys Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mineralys Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Mineralys Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Mineralys Therapeutics (Mineralys Therapeutics) Business Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MLYS has been successfully added to your 